Shareholders' Equity (Deficit) - Narrative (Details) $ / shares in Units, $ in Thousands		1 Months Ended					2 Months Ended	3 Months Ended
	Jan. 01, 2021 USD ($) shares	Mar. 31, 2021 USD ($) $ / shares shares	Jan. 31, 2021 USD ($) shares	Sep. 30, 2020 USD ($) $ / shares shares	Feb. 29, 2020 USD ($) shares	Jan. 31, 2020 USD ($) $ / shares shares	Feb. 29, 2020 USD ($)	Mar. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2020 USD ($) shares	Jan. 04, 2021 shares	Dec. 31, 2020 USD ($)
Sale of Stock [Line Items]
Proceeds from sale of common stock		$ 229,500					$ 282,833	$ 308,743	$ 283,333
Other offering expenses								500	340
Payment for license agreement								0	20,750
Issuance of common shares as payment for assets								10,243
Equity Distribution Agreement aggregate amount											$ 400,000
Noncontrolling interest								$ 360	$ 0
Kleo
Sale of Stock [Line Items]
Ownership percentage (percent)											41.90%
Yale University | License agreement | Yale MoDE Agreement
Sale of Stock [Line Items]
Payment for license agreement			$ 1,000
Issuance of common shares as payment for assets (in shares) | shares			11,668
Issuance of common shares as payment for assets			$ 1,000
Moda Pharmaceuticals LLC | License agreement | Moda Agreement
Sale of Stock [Line Items]
Payment for license agreement	$ 2,700
Issuance of common shares as payment for assets (in shares) | shares	37,836
Issuance of common shares as payment for assets	$ 3,243
Common Shares
Sale of Stock [Line Items]
Common stock issued (shares) | shares								4,037,204	5,555,554
Issuance of common shares as part of acquisition (in shares) | shares								115,836
Issuance of common shares as payment for assets (in shares) | shares								110,998
Issuance of common shares as payment for assets								$ 10,243
Kleo
Sale of Stock [Line Items]
Shares of common stock exchanged for each share of acquiree | shares										0.007
BioShin 2020 Equity Incentive Plan
Sale of Stock [Line Items]
Requisite service period of award (in years)				3 years
Minimum
Sale of Stock [Line Items]
Requisite service period of award (in years)								3 years
Maximum
Sale of Stock [Line Items]
Requisite service period of award (in years)								4 years
Series A preferred shares | Minimum
Sale of Stock [Line Items]
Preferred shares call and put options execution multiple following change of control				2.5
Series A preferred shares | Maximum
Sale of Stock [Line Items]
Preferred shares call and put options execution multiple following change of control				3.5
Series A-2 preferred stock | Artizan Biosciences Inc
Sale of Stock [Line Items]
Preferred shares paid (in shares) | shares			61,494
Preferred shares paid			$ 6,000
Preferred shares received (in shares) | shares			34,472,031
Public offering
Sale of Stock [Line Items]
Common stock issued (shares) | shares		2,686,409				4,830,917
Issuance price per share (in dollars per share) | $ / shares		$ 76.00				$ 51.75		$ 76.00
Proceeds from sale of common stock		$ 199,500				$ 245,877
Underwriting discounts and commissions		4,167				3,623
Other offering expenses		$ 500				$ 500
Over-allotment option
Sale of Stock [Line Items]
Common stock issued (shares) | shares		402,961			724,637
Proceeds from sale of common stock		$ 30,000			$ 36,956
Underwriting discounts and commissions		$ 625			$ 543
Equity Distribution Agreement
Sale of Stock [Line Items]
Common stock issued (shares) | shares								939,328
Proceeds from sale of common stock								$ 78,743
BioShin Preferred Shares | Series A preferred shares
Sale of Stock [Line Items]
Preferred stock issued and sold (in shares) | shares				15,384,613
Shares issued price per share | $ / shares				$ 3.90
Proceeds from shares issued				$ 60,000